This study aimed to investigate the correlation of pro-angiogenic micro-RNA (miRNA) expressions with rapid angiographic stenotic progression (RASP) and restenosis risks in coronary artery disease (CAD) patients underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
| INTRODUC TI ON
Coronary artery disease (CAD) is the leading cause of deaths in both developing and developed countries with the annual deaths more than 17.5 million worldwide, accounting for approximately one third of all-cause deaths. [1] [2] [3] In clinical practice, there are several revascularization treatments for CAD, such as percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), and drug therapy, among which PCI represents the most common therapy for CAD patients, and PCI with drug-eluting stents (DES) achieves significant relief of clinical symptoms and reduction in mortality in CAD patients compared with previous baremetal stents (BMS). [4] [5] [6] [7] [8] [9] However, in clinical practice, CAD patients underwent PCI with DES may also present with rapid angiographic stenotic progression (RASP) at nontarget lesion and restenosis at stented lesion in CAD patients. Although antiproliferative drugs loaded in stents are designed to reduce the occurrence of RASP as well as restenosis which have made some progresses, especially restenosis rate could decrease to 3%-20%, while the incidences of RASP and restenosis are still not negligible due to a very large CAD population treated by PCI with DES. [10] [11] [12] [13] Hence, it is meaningful to explore better strategies for predicting RASP and restenosis risks in CAD patients underwent PCI with DES, thereby guiding optimization of clinical treatment strategies and taking preventive measures as soon as possible.
Angiogenesis is of great importance in the development and progression of CAD by expanding microvascular network and assisting vascular repair to improve vascular functions. 14 Accordingly, proangiogenic microRNA (miRNA) is a class of approximately 20-25 nt, single-stranded noncoding RNAs that regulate vascular functions through post-transcriptional modulation of anti-angiogenic genes expressions, and a few pro-angiogenic miRNAs have been identified until now. [15] [16] [17] For instance, miR-130a induces angiogenesis through targeting C-MYB in vascular endothelial cells 15 ; miR-126 and miR-210 improve angiogenesis and then present with cardioprotective effect in rat. 17 Since angiogenesis is benefiting for the microvascular network rebuilding and vascular repair, we hypothesized that pro-angiogenic miRNA expressions might correlate with the risks of RASP and restenosis in CAD patients underwent PCI with DES, while no related data have been reported. Therefore, we selected 14 pro-angiogenic miRNAs referring to a previous comprehensive review on angiogenesis-related miRNAs, 18 and this study aimed to explore the correlation of these 14 pro-angiogenic miRNA expressions with RASP and restenosis risks in CAD patients underwent PCI with DES.
| ME THODS

| Participants
During the period from January 2012 to December 2016, 286 CAD patients who underwent PCI with DES implantation at the Central Hospital of Wuhan were consecutively recruited in this study. The inclusion criteria included (a) confirmed diagnosis of severe CAD based on the coronary angiography, which was defined as the luminal stenosis ≥70% in at least one major coronary vessel, (b) age ≥18 years old, (c) scheduled to undergo PCI with DES implantation, and (d) able to be regularly followed up. Patients were excluded if they (a) had contraindications to the PCI, (b) were allergic to the medications: clopidogrel, rapamycin, paclitaxel, stainless steel, or cobalt alloy, (c) previously underwent major surgery, PCI, or coronary artery bypass grafting, (d) received treatment with immunosuppressive drugs within 3 months, (e) complicated with inflammatory diseases, autoimmune diseases, (f) with a history of severe infection or malignancies, and (g) were pregnant women or lactating women. The present study was approved by the Institutional Review Board of the Central Hospital of Wuhan and conducted in accordance with the Declaration of Helsinki. All patients provided the written informed consents before enrollment.
| Data collection
After the eligibility was confirmed and the informed consents were provided, patients' baseline features were recorded, which included age, gender, body mass index (BMI), smoke, hypertension, diabetes mellitus, hypercholesteremia, hyperuricemia, and family history of CAD and left ventricular ejection fraction (LVEF), and the laboratory detections were also recorded including mean arterial pressure (MAP), fasting blood glucose (FBG), serum creatinine (Scr), serum uric acid (SUA), cardiac troponin I (cTnI), N-terminal pro-brain natriu- 
| Measurement of candidate miRNAs
Blood samples were collected from all patients before PCI and centrifuged at 880 g for 10 minutes to separate plasma. Total RNA was extracted from the plasma using TRIzol solution (Invitrogen) according to the manufacturer's protocol. The extracted RNA in solution was stored at −80°C until use. RNA concentration and purity from all samples were measured using NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific). The integrity of RNA was determined by 1.2% agarose electrophoresis (Sigma). Before real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR) was performed, the complementary DNA (cDNA) was synthesized from total RNA using a RevertAid RT Reverse Transcription Kit (Thermo Fisher Scientific) following the manufacturer's instructions. RT-qPCR was carried out on an Applied Biosystems 7900 HT thermocycler (Applied Biosystems) with TB Green™ Fast qPCR Mix (Takara), and the reactions were incubated at 95°C for 3 minutes, followed by 40 cycles of 95°C for 5 seconds and 61°C for 30 seconds. All reactions were run in triplicate. Relative quantitation of gene expression was analyzed by the 2 −ΔΔCq method, and the U6 was utilized as an internal reference for normalizing miRNA quantity. The primers used in the study are listed in Table S1 .
| Quantitative coronary angiography (QCA) analysis
The procedures of PCI and DES implantation and the perioperative managements were performed in accordance with the recommendations of the guidelines of PCI, and the rapamycin-eluting stent and paclitaxel-eluting stent were used as DES (the choice of stent depended on the patients' willingness). Quantitative coronary angiography was performed before PCI (baseline), post-operation, and at 12th month after PCI or earlier if indicated by clinical symptoms or evidence of myocardial ischemia. Coronary angiograms were obtained after intracoronary nitroglycerin administration. Baseline, postoperative, and follow-up coronary angiograms were digitally recorded, and the QCA analyses were performed with an automated edge-detection system (Medis Medical Imaging Systems) by experienced specialists.
| Definitions
Rapid angiographic stenotic progression of nontarget lesion and restenosis of stented lesions were evaluated by QCA. Rapid angiographic stenotic progression of nontarget lesion was defined as the occurrence of any of the following conditions 19 
| Statistics analysis
| Baseline characteristics
The mean age of CAD patients was 60.4 ± 9.6 years with mean BMI 25.9 ± 3.4 kg/m 2 , and 232 (81.1%) males as well as 54 (18.9%) females were included (Table S2 ). There were 216 (75.5%), 165 (57.7%), Table S2 .
| The occurrence rates of RASP and restenosis
There were 113 cases (39.5%) and 64 cases (22.4%) occurred RASP and restenosis, respectively, in CAD patients underwent PCI with DES implantation (Figure 2 ).
| Comparison of pro-angiogenic miRNA expression levels between RASP and non-RASP patients
Compared to non-RASP patients, RASP patients exhibited lower expression levels of let-7f (P < .001) ( Figure 3B ), miR-19a (P < .001) ( Figure 3F ), miR-19b-1 (P = .017) ( Figure 3G ), miR-92a (P = .010) ( Figure 3I ), miR-126 (P < .001) ( Figure 3J ), miR-210 (P < .001) ( Figure 3L ), and miR-296 (P = .011) ( Figure 3M ) at baseline, while there was no difference in the other seven candidate miRNA expression levels between non-RASP and RASP patients at baseline, including let-7b ( Figure 3A) , miR-17-5p ( Figure 3C ), miR-17-3p ( Figure 3D ), miR-18a ( Figure 3E ), miR-20a ( Figure 3H ), miR-130a ( Figure 3K ), and miR-378 ( Figure 3N ). (Table S3 ). 
| Correlation of pro-angiogenic miRNA expressions with RASP risk
| Predictive value of pro-angiogenic miRNAs for RASP risk determined by ROC curves
Since let-7f, miR-19a, miR-126, miR-210, and miR-296 independently correlated with decreased RASP occurrence, ROC curve analysis was further carried out to evaluate their predictive value for RASP risk, which disclosed that let-7f (AUC: 0.709, 95% CI: 0.649-0.768), miR-19a (AUC: 0.674, 95% CI: 0.613-0.736), miR-126 (AUC: 0.733, 95% CI: 0.675-0.790), miR-210 (AUC: 0.713, 95% CI: 0.655-0.771), and miR-296 (AUC: 0.589, 95% CI: 0.523-0.654) could predict RASP risk ( Figure 4) . Moreover, combination of all these five miRNAs displayed even better predictive value for RASP risk with AUC 0.879 (95% CI: 0.841-0.917).
| Comparison of pro-angiogenic miRNA expression levels between restenosis and nonrestenosis patients
Compared to non-restenosis patients, restenosis patients displayed decreased expression levels of let-7f (P = .001) ( Figure 5B ), miR-19a (P < .001) ( Figure 5F ), miR-92a (P = .042) ( Figure 5I ), miR-126 (P < .001) ( Figure 5J ), miR-130a (P = .021) ( Figure 5K) , and miR-210 (P = .002) ( Figure 5L ) at baseline, whereas the other candidate eight miRNA expression levels did not differ between non-restenosis and restenosis patients at baseline, including let-7b ( Figure 3A) , miR-17-5p ( Figure 3C ), miR-17-3p ( Figure 3D ), miR-18a ( Figure 3E ), miR-19b-1 ( Figure 3G ), miR-20a ( Figure 3H ), miR-296 ( Figure 3M ), and miR-378 ( Figure 3N ). Figure 6 ). Furthermore, combination of all these four miRNAs exhibited higher predictive value for restenosis risk with AUC 0.776 (95% CI: 0.722-0.831).
| Correlation of pro-angiogenic miRNA expressions with restenosis risk
| Predictive value of pro-angiogenic miRNAs for restenosis risk determined by ROC curves
| D ISCUSS I ON
In the present study, we observed that in CAD patients underwent [20] [21] [22] As to restenosis, it occurs at stented sites probability due to the vulnerability of stented arteries and the effect of regeneration of endothelium, which manifests as distinct neointimal hyperplasia at stented sites. 21, 22 Briefly, RASP and restenosis derive from several adverse effects caused by stent implantation, including endothelial cell (EC) dysfunction, ectopic proliferation, and migration of VSMCs as well as inflammatory reaction. 3, 22 Recently, accumulating studies disclose that pro-angiogenic miR-NAs play critical roles in vascular remodeling and pathophysiology of cardiovascular diseases. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] For instance, miR-126, as a common reported pro-angiogenesis gene, promotes vessel wound healing and attenuates development of cardiovascular pathology by inducing angiogenesis and vascular regeneration in vascular injury and ischemic conditions, 23, 24 and improves angiogenic function of ECs or endothelial progenitor cells (EPCs) via regulating epidermal growth factor-like domain 7 (EGFL7) 25 ; meanwhile, it reduces ectopic VSMC proliferation and limits neointima formation by inhibiting low-density lipoprotein receptor-related protein 6 (LRP6). 28 In addition, miR-126 is also a negative regulator of inflammation, which is a key contributor to cardiovascular pathology, including endothelial dysfunction and ectopic proliferation and migration of VSMCs. [26] [27] [28] As to another common pro-angiogenic miRNA, miR-92a facilitates angiogenesis via upregulating vascular endothelial growth factor A (VEGFA) and re-endothelialization, preventing neointima formation following vascular injury, 30, 31 and it protects VSMCs against apoptosis via suppressing of both mitogen-activated protein kinase 4 (MKK4) and c-Jun N-terminal kinase (JNK) pathways in vascular remodeling of several vascular diseases, such as aneurysms, post-angioplasty restenosis, and atherosclerosis, which leads to inhibition of plaque instability and rupture. 32 Furthermore, another pro-angiogenic miR-210 is also observed to accelerate angiogenesis via activating notch signaling pathway and able to decrease inflammatory cells density as well as reduce the apoptosis and dysfunction of ECs through inhibiting the receptor tyrosine kinase ligand Ephrin-A3, protecting from vascular ischemic damage. [33] [34] [35] Considering the functions of pro-angiogenesis miRNAs in vascular remodeling and the pathological processes of RASP and restenosis in blood vessels, we hypothesized that pro-angiogenic 38 Another study illuminates that peripheral blood miR-210 correlates with decreased risk of chronic obstructive pulmonary disease combined with ischemic stroke. 39 Besides, a recent study also observes that miR-126, miR-17-5p, miR-92a, miR-210, and miR-378 independently correlate with reduced risk of CAD and disease progression (assessed by Gensini score). 40 These data provide evidences for the potential of (MKP-1) and vascular cell adhesion molecule-1 (VCAM-1), leading to amelioration of endothelial dysfunction and suppression of ectopic VSMC proliferation. 41, 42 There were several limitations in this study. Firstly, angiographic surveillance of RASP and restenosis might elevate the restenosis rate; hence, other alternatives of assessment could be utilized, such as intravascular ultrasonography, optical coherence tomography, and fractional flow reserve. 43 Secondly, we only assessed the shortterm incidence of RASP or restenosis in CAD patients underwent PCI with DES; thereby, further study would be performed with longer follow-up time. Thirdly, this was a single-center study with relatively low patients which might lead to patient selection bias and reduced statistical efficiency; thus, further study with more medical centers and patients should be conducted in the future.
In conclusion, circulating let-7f, miR-19a, miR-126, miR-210, and miR-296 independently correlate with reduced RASP risk, while miR-19a, miR-126, miR-210, and miR-378 independently correlate with decreased restenosis risk in CAD patients underwent PCI with DES.
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